elite p die Bereinigung/Gruss an schneemann

ich singe beim Ordern ..das ist schön für Bett und Depot ..und fetzt

Zeit  Kurs  Stück  
18:06:48 0,082 $  10.500  
18:06:38 0,082 $  14.000  
18:06:24 0,083 $  4.000  
17:57:29 0,083 $  13.735  
17:57:22 0,083 $  800  
17:41:07 0,082 $  30.000  
17:40:38 0,082 $  13.000  
17:35:13 0,082 $  10.000  
17:00:42 0,082 $  2.000  
16:54:25 0,0821 $  13.000  
16:49:51 0,087 $  44.000  
16:41:23 0,087 $  3.000  
16:41:10 0,087 $  7.500  
16:41:09 0,087 $  18.000  
16:39:30 0,086 $  30.000  
16:39:28 0,086 $  69.875  
16:39:12 0,082 $  13.000  
16:29:13 0,0869 $  2.000  
16:27:18 0,086 $  15.000  
16:27:12 0,086 $  10.000  
16:26:55 0,086 $  1.300  
16:26:12 0,086 $  10.000  
16:20:31 0,086 $  11.000  
15:58:20 0,087 $  2.300  
15:55:15 0,081 $  15.000  
15:55:07 0,081 $  15.000  
15:47:59  0,0821 $  24.800  
15:46:25 0,0822 $  3.000  
15:46:21 0,084 $  10.000  
15:32:33 0,085 $  14.000  
15:30:14 0,085 $  25.000  
15:30:13 0,085 $  100

buran  

stolpert das klein Hänschenklein

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.08.13 0,0826 0,0827 0,078  0,08 $ 847.065 68 T

da sah und sprach das schöne Elite P Börsen Lieschen:: Hänschen lass das Börsen Parkett Stolpern sein und order für RT 0,054 € die Elite P doch nun mal fix ein

Hänschenklein,Börsen Lieschen & buran  

Datum Erster Hoch Tief Schluss     Stücke Volumen
06.09.13 0,082 0,0822 0,078  0,0815 $ 1.006.742 80 T

ist Euch das schon mal aufgefallen? ..trotz Rauchverbot in Flugzeugen gibt es auf den Bord Toiletten Aschenbecher ..wieso? ..weiss das wer?

einfach mal so machen @buran

buran,Der Börsen Flug Kapitano  

specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.
http://www.elitepharma.com/  

Elite Pharmaceuticals Press Release for: Tuesday, September 03, 2013



ELITE PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE 15TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY SEPTEMBER 8-10TH


Northvale, New Jersey, Tuesday, September 03, 2013: Elite Pharmaceuticals, Inc. (OTC BB: ELTP), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.

Nasrat Hakim, President and CEO of Elite, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodm.com ) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the
Company.

Event: 15th Annual Rodman & Renshaw Global Investment Conference

Date: September 10, 2013

Time: 12:05 PM Eastern Time

Location: Room 7.02, 7th Floor; Millennium Broadway Hotel in New York City

The presentation will be webcast live. To access the webcast, please visit www.rodm.com or www.elitepharma.com . The webcast replay will remain available for 90 days following the live presentation.
About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has six commercial products currently being sold, an additional product approved and soon to be launched, eleven approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.


Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com


This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company’s ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.


http://www.elitepharma.com/investor_relations.asp?goto=365  

XBRL INSTANCE DOCUMENT: EX-101.INS
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT: EX-101.SCH
XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT: EX-101.CAL
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE: EX-101.DEF
XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT: EX-101.LAB
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT: EX-101.PRE
http://www.elitepharma.com/XBRL-listings.asp?f=eltp-2011-08-15-10Q  

http://money.msn.com/business-news/...px?iview=keydev&symbol=ELTP GrB  

DETAILS. Symbol  Value ($)  
Previous Close  0.11  
Open  0.11  
Day's High  0.11  
Day's Low  0.10  
Volume  5.59 Mil  
Avg Daily Vol (13 Wks)  NA  
Bid  0.10  
Bid Size  5,000  
Ask  0.11  
Ask Size  5,000  
52-Wk High  NA  
52-Wk Low  NA  
Dividend Rate  NA  
Yield  NA  

Last trade 9/16/2013 3:59 PM ET
http://investing.money.msn.com/investments/stock-price?symbol=ELTP  

http://www.marketwatch.com/story/...ltrexone-hydrochloride-2013-09-18  

heute wieder rauf  

RTK 0,117 $ RTP +9,45 EK 0,1069 $ last 4.000 RT gesamt 3.977.919 peak 0,1199 ,GrB  

an Medikamenten nachkommt. Der CEO bringt ja ne Menge an Know-How mit. Er war schließlich Vizepräsident von Actavis, einem Nasdaq-Pharma Konzern mit mehreren Mrd. Marketcap.


 

http://seekingalpha.com/article/...ceuticals-call-it-a-comeback-story

liest sich gut, Finanzierung wieder gesichert, CEO lässt sich nur durch Aktienoptionen bezahlen, mehrere FDA zugelassene Medikamente bringt er mit und weitere stehen in der Entwicklung.  

Datum Erster Hoch Tief Schluss     Stücke Volumen
18.09.13 0,112 0,1325 0,1071  0,13 $ 9.902.747 1,18 M

GrB  

 

 

Elite Pharma Inc(OTCQB: ELTP)
0.16  +0.03 +19.23%
Previous Close  0.13  
Open  0.13  
Day's High  0.17  
Day's Low  0.13  
Volume  15.38 Mil  
Avg Daily Vol (13 Wks)  NA  
Bid  0.05  
Bid Size  10,000  
Ask  0.21  
Ask Size  2,500  
52-Wk High  NA  
52-Wk Low  NA  
Dividend Rate  NA  
Yield  NA  

Last trade 9/19/2013 3:59 PM ET
http://investing.money.msn.com/investments/stock-price?symbol=ELTP  

(GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of naltrexone hydrochloride 50 mg tablets under the License, Manufacturing and Supply Agreement with its sales and marketing partner, triggering a milestone payment. Elite's sales and marketing partner will distribute the product as part of a multi-product distribution agreement.

Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. For the calendar year 2012, Revia and its generic equivalents had total U.S. sales of approximately $16 million according to IMS Health Data.

"With the shipment of naltrexone, Elite has now launched seven products in less than two and a half years," commented Nasrat Hakim, Elite's President and CEO. "The Company has executed the strategic plan on schedule. This plan now includes an additional thirteen products, eleven of which are approved, and are prioritized for commercialization pending manufacturing site transfer."

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, eleven approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.
http://money.msn.com/business-news/...p;date=20130918&id=16911258  

Preis 0,126 € Schleife 10.000 spread 21,15% / RTK  0,104 € RTP +19,54 Pott +160,84% ,GrB  

0,1595 $ +2,90% +0,0045 $ In Euro: 0,1179 € | Nasdaq OTC BB, 21:59 ,GrB  

0.16  0.00(2.90%) 3:59PM EDT

Prev Close: 0.16
Open: 0.16
Bid: N/A
Ask: N/A
1y Target Est: 4.00
Beta: 0.37
Next Earnings Date: N/A
Day's Range: 0.15 - 0.16
52wk Range: 0.05 - 0.17
Volume: 8,257,277
Avg Vol (3m): 1,987,350
Market Cap: 64.35M
P/E (ttm): 13.29
EPS (ttm): 0.01
Div & Yield: N/A (N/A)
http://finance.yahoo.com/q?s=ELTP&ql=1  

Form 8-K for ELITE PHARMACEUTICALS INC /NV/
http://biz.yahoo.com/e/130918/eltp8-k.html GrB  

:::::::::::::: 0,1172 $ +1,91% +0,0022 $ In Euro: 0,0866 € | Nasdaq OTC BB ,GrB  

RTK 0,1179 $ RTP +2,52 EK 0,115 $ last 3.701 full 2.069.986 peak 0,118

buran und danke und weitermachen ..immer schneller immer schneller wie PROPELLER

buran,Der Börsen Propeller Mann  

Datum Erster Hoch Tief Schluss     Stücke Volumen
16.10.13 0,13 0,132 0,124  0,1271 $ 776.091 99 T

GrB